Vascular Regeneration by Stem/Progenitor Cells.
Yao Xie,Ye Fan,Qingbo Xu
DOI: https://doi.org/10.1161/ATVBAHA.116.307303
2016-01-01
Abstract:Cardiovascular disease is a major cause of death worldwide. Many cardiovascular events, such as stroke and coronary heart disease, strongly correlate with loss of blood supply, leading to loss of cell function, organ failure, and eventually death.1 Vascular regeneration, which includes restoration of normal vascular structure and function, the reversal of vascular senescence, and the growth of new blood vessels may be a promising approach for the treatment of these diseases.2 Stem/progenitor cells are able to differentiate into vascular cell lineages, which may contribute to the regenerative process and could be useful for the disease treatment.3 Recently, several publications in Arteriosclerosis, Thrombosis, and Vascular Biology and other journals have demonstrated great progress in research into stem/progenitor cells for vascular regeneration.4–6 In the present article, we will highlight these updated publications, providing insights into the role of stem/progenitor cells in restoration of vascular function under pathophysiological conditions and the contribution of these cells to lesion formation in the vessel wall through the mechanisms of cell migration and differentiation.Since the discovery of hemangiogenic cells in the bone marrow, researchers have been searching for other such pools of circulating progenitors, such as those that may contribute to vascular repair after ischemic injury. The study of circulating endothelial progenitors, termed endothelial progenitor cells (EPCs), became an extremely attractive field of research after they were first isolated by Asahara et al7 in 1997, using magnetic bead selection based on expression of specific cell surface antigens. Though a large number of articles have since been published using the term EPCs,8–10 its initial use was a misnomer because the surface markers used for cell isolation and characterization, such as vascular endothelial growth factor receptor 2 (VEGFR2) and CD133,11 are …